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Abstract
Tetherin (CD317/BST2) is an interferon-induced membrane protein that inhibits the release of diverse enveloped viral
particles. Several mammalian viruses have evolved countermeasures that inactivate tetherin, with the prototype being the
HIV-1 Vpu protein. Here we show that the human herpesvirus Kaposi’s sarcoma-associated herpesvirus (KSHV) is sensitive to
tetherin restriction and its activity is counteracted by the KSHV encoded RING-CH E3 ubiquitin ligase K5. Tetherin expression
in KSHV-infected cells inhibits viral particle release, as does depletion of K5 protein using RNA interference. K5 induces a
species-specific downregulation of human tetherin from the cell surface followed by its endosomal degradation. We show
that K5 targets a single lysine (K18) in the cytoplasmic tail of tetherin for ubiquitination, leading to relocalization of tetherin
to CD63-positive endosomal compartments. Tetherin degradation is dependent on ESCRT-mediated endosomal sorting, but
does not require a tyrosine-based sorting signal in the tetherin cytoplasmic tail. Importantly, we also show that the ability of
K5 to substitute for Vpu in HIV-1 release is entirely dependent on K18 and the RING-CH domain of K5. By contrast, while Vpu
induces ubiquitination of tetherin cytoplasmic tail lysine residues, mutation of these positions has no effect on its
antagonism of tetherin function, and residual tetherin is associated with the trans-Golgi network (TGN) in Vpu-expressing
cells. Taken together our results demonstrate that K5 is a mechanistically distinct viral countermeasure to tetherin-mediated
restriction, and that herpesvirus particle release is sensitive to this mode of antiviral inhibition.
Citation: Pardieu C, Vigan R, Wilson SJ, Calvi A, Zang T, et al. (2010) The RING-CH Ligase K5 Antagonizes Restriction of KSHV and HIV-1 Particle Release by
Mediating Ubiquitin-Dependent Endosomal Degradation of Tetherin. PLoS Pathog 6(4): e1000843. doi:10.1371/journal.ppat.1000843
Editor: Jae U. Jung, University of Southern California School of Medicine, United States of America
Received April 22, 2009; Accepted March 3, 2010; Published April 15, 2010
Copyright:  2010 Pardieu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by a Wellcome Trust Research Career Development Fellowship to SJDN (WT082274MA) and a Wellcome Trust Senior Research
Fellowship to GJT (076608). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: g.towers@ucl.ac.uk (GJT); stuart.neil@kcl.ac.uk (SJDN)
. These authors contributed equally to this work.
Introduction
The inhibitory effect of type 1 interferons (type 1 IFN) on the
replication of mammalian viruses has been documented for over
50 years. However the effecter mechanisms that interfere with
virus replication have not been well characterized. While many
IFN response genes are known, few definitive antiviral functions
have been ascribed to them. Amongst the best characterized are
PKR/2959oligoadenylate synthetase, MxA and ISG15, all of
which have broad activity against a variety of mammalian RNA
viruses [1]. Recently the identification of retroviral restriction
factors including members of the APOBEC3 family of cytidine
deaminases, as well as TRIM5 and other members of the tripartite
motif protein family, has highlighted innate intracellular defense
mechanisms as key determinants of tropism for human and
primate immunodeficiency viruses [2,3]. Moreover, these antiviral
activities have driven the acquisition of viral countermeasures [2,4]
and thus interferon-inducible restriction factors are now thought to
represent an important arm of the antiviral innate immune system
[3].
Tetherin, (BST2/CD317) has recently been shown to inhibit
the release of HIV-1 particles that are defective for the accessory
protein Vpu [5,6]. In the absence of Vpu expression, nascent
HIV-1 particles assemble at the plasma membrane but remain
tethered to the surface of tetherin expressing cells via a protease-
sensitive linkage. Tethered virions are then endocytosed leading to
their accumulation in late endosomes [5,7,8]. Tetherin colocaliza-
tion with restricted viral particles on cell surfaces and in
endosomes is well documented [5,6,9]. Strikingly, it is tetherin’s
unusual topology that is thought to be directly responsible for its
mode of action [10]. Tetherin is a dimeric type-II membrane
protein consisting of an N-terminal cytoplasmic tail, an extracel-
lular domain with a putative coiled coil, and a C-terminal GPI
anchor which is required for its antiviral function [5,11]. It forms
dimers which are thought to cross-link viral and cellular
membranes during viral budding [10]. Tetherin appears to have
no direct association with any viral structural proteins and is
therefore able to restrict a range of unrelated viruses including
retroviruses, filoviruses and arenaviruses [9,12,13]. It is expressed
on mature B cells and plasmacytoid dendritic cells, but can be
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induced in many cell types by type-I interferon (IFN)
[8,14,15,16,17]. Sequence analysis of orthologues of tetherin from
primates indicates high levels of positive selection during their
evolution suggesting selective pressure from pathogenic viral
infections [18,19]. Together, these observations suggest that
tetherin may be an important antiviral defense against enveloped
virus replication, necessitating the acquisition of viral counter-
measures to antagonize its activity.
Interestingly, other potential viral countermeasures to tetherin
may exist. Kaposi’s sarcoma-associated herpesvirus (KSHV), also
known as Human herpesvirus 8 (HHV8), encodes two immuno-
modulatory membrane associated RING-CH (MARCH) E3
ubiquitin ligases named K3 and K5 [20]. K5 has been shown to
mediate the down-regulation of a variety of cell surface markers
including MHC class I, PE-CAM-1, CD80/CD86, ICAM-1,
IFNc receptor and NKG2D [21,22,23,24,25,26,27]. In a recent
proteomics screen Bartee and colleagues used a methodology
called stable isotope labeling of amino acids in cultured cells
(SILAC) to identify proteins that are removed from the plasma
membrane on K5 expression. One of the novel K5 targets found
was tetherin (BST2) [28]. Here we have tested the hypothesis that
tetherin restricts assembly/release of KSHV particles and that an
important function of K5 is to overcome this process.
Results
KSHV particle release is sensitive to tetherin-mediated
restriction
Tetherin has the capacity to restrict the release of diverse
enveloped viruses including filoviruses and arenaviruses [9,12,13].
Given the capacity of the KSHV protein K5 to reduce cell surface
expression of tetherin [28] we tested whether KSHV could be
restricted by the expression of increasing amounts of exogenous
human tetherin. We reasoned that the complex envelopment
strategy of herpesviruses [29] and the tropism of KSHV for
tetherin-positive mature B cells made this virus potentially sensitive
to restriction by tetherin. To test this we generated a HeLa cell line
harboring latent recombinant rKSHV.219 episomes under
puromycin selection which encode eGFP driven by the human
EF-1a promoter and DsRed driven by the KSHV PAN promoter
that responds to the KSHV immediate early protein RTA [30].
Transfection of these cells with an RTA encoding plasmid (pCMV
RTA) induces KSHV transcription, lytic replication and the
release of KSHV particles, the efficiency of which can be assessed
by measurement of RFP expression. The amount of virus released
48h post-RTA induction can be measured by quantitative PCR
(Q-PCR) detecting DNAse-I protected genomes in the supernatant
or by titration of infectious virus onto 293T cells and enumeration
of GFP expressing cells by flow cytometry.
We first determined whether transfecting a plasmid expressing
tetherin together with pCMV-RTA would impact on the amount of
infectious virions released into the supernatant. Figure 1A clearly
demonstrates a linear decrease in release of KSHV infectious virus
when increasing amounts of the tetherin-expressing plasmid are
transfected with a constant amount of pCMV-RTA. Similarly, Q-
PCR performed on DNAse-I resistant genomes showed a greater
than 10-fold decrease in total virions released for the highest dose of
tetherin-expressing plasmid used (Figure 1B). To control for
transfection efficiency, cells were recovered after virus collection
and cell lysates subjected to western blotting (Figure 1C). As expected,
increasing amounts of tetherin were detected as increasing amounts
of tetherin-expressing plasmid was transfected. Importantly, equal
RTA expression was found in all samples confirming that RTA levels
were not impacted by tetherin expression. To further rule out an
effect of tetherin expression on KSHV reactivation we also measured
lytic viral RNA production by quantitative RT-PCR. Ct values for
ORF37 were normalized to those obtained for cellular GAPDH.
Figure 1D shows very similar ORF37/GAPDH ratios for each
condition.Whilst unlikely, it is also possible that exogenous expression
of increasing amounts of tetherin might lower genomic replication,
thus leading to a reduced amount of virions and/or DNase-I resistant
genomes in the supernatant. To rule this out we measured
intracellular episomes in DNA extracts by Q-PCR. Figure 1E clearly
demonstrates that episome copy number was similar across all
conditions and could not account for reduced viral production.
Reduction of K5 expression using K5 specific shRNA
reduces KSHV release
We then tested whether K5 expression was required for efficient
KSHV release from r219-HeLa cells. We reasoned that if K5 is a
KSHV antagonist for tetherin then reducing its expression by
RNA interference (RNAi) should inhibit KSHV release. Three
shRNA hairpins were designed and expressed in 293T cells
together with a HA-tagged K5 protein. Reduction of K5
expression by the hairpins was assessed by recovering the cells
48 hours after transfection and subjecting the lysates to western
blot (Figure 2A). Blots probed with the anti-HA antibody were
stripped and re-probed for alpha tubulin to control for equal
loading (Figure 2A). All three hairpins reduced K5 expression with
hairpin 3 (sh-K5iii) being the most potent. We then expressed the
hairpins in r219-HeLa cells using lentiviral vectors [31]. 72 hours
later the cells were re-seeded and transfected with RTA to induce
KSHV lytic replication. Release of infectious KSHV was
measured by titration of supernatants on 293T as before
(Figure 2B). We found that expression of specific anti-K5 shRNA
reduced KSHV titer in the supernatant whereas expression of an
empty shRNA vector did not (Figure 2B). The number of DNAse-I
resistant KSHV genomes in the supernatant was also reduced by
all three shRNA vectors, as shown by taqman Q-PCR (Figure 2C).
Messenger RNA for the late gene ORF37 was measured by
quantitative RT-PCR in each sample and values were corrected
Author Summary
To replicate efficiently in their hosts, viruses must avoid
antiviral cellular defenses that comprise part of the innate
immune system. Tetherin, an antiviral membrane protein
that inhibits the release of several enveloped viruses from
infected cells, is antagonized by the HIV-1 Vpu protein. The
K5 protein of the human pathogen Kaposi’s sarcoma-
associated herpesvirus (KSHV) modulates the cell surface
levels of several host proteins including tetherin. We show
that KSHV release is sensitive to tetherin, and that K5
expression is required for efficient virus production in
tetherin-expressing cells. K5 is also capable of rescuing
Vpu-defective HIV-1 virus release from tetherin. K5
expression induces a down-regulation of cell-surface
tetherin levels and degradation in late endosomes, which
depends on a single lysine residue in the tetherin
cytoplasmic tail. Finally, we show that the ESCRT pathway,
which promotes the trafficking of cell surface receptors for
degradation, is required for K5-mediated tetherin removal
from the plasma membrane. Thus, we demonstrate that
herpesviruses are sensitive to the antiviral effects of
tetherin and that KSHV has evolved a mechanism for its
destruction. These findings extend the list of viruses
sensitive to tetherin, suggesting that tetherin counter-
measures are widespread defense mechanisms amongst
enveloped viruses.
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Figure 1. Over-expression of human tetherin restricts KSHV particle release. HeLa KSHV cells were transfected with an expression vector
encoding the KSHV early transcriptional activator RTA and increasing doses of pCR3.1 encoding human tetherin. Plasmid dose was kept constant
using pcDNA3.1. 48 hours after transfection supernatants were harvested, filtered and used to infect 293T cells (A) and infectious virus titer
determined by GFP expression in the target cells by flow cytometry. Values are presented as infectious units/ml. (B) Parallel supernatants were
treated for 2 hours with DNase-I and viral genomic DNA isolated and supernatant genome copy number enumerated by quantitative Taqman PCR
specific for ORF37. Values are presented as copies/ml. (C) Western blot analysis for RTA protein (top panel) performed on r219-HeLa cells after virus
collection indicates that RTA expression levels were equivalent in each sample. Blots were stripped and detection of tetherin using an anti-HA
antibody performed (middle panel) shows increasing tetherin levels across samples, as expected. Alpha tubulin was detected concomitantly to RTA
to demonstrate equal loading (bottom panel). (D) KSHV reactivation was equivalent in all samples as evidenced by measurement of ORF37 mRNA
levels by quantitative Taqman PCR and after normalization to GAPDH levels. (E) KSHV genome levels remained constant in all samples as evidenced
by equivalent numbers of intracellular KSHV episomes per nanogram of total cellular DNA. Results are the mean of 2 independent experiments and
errors are standard error of the mean.
doi:10.1371/journal.ppat.1000843.g001
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for cellular GAPDH mRNA levels. This demonstrated that
hairpin expression did not significantly inhibit KSHV reactivation
(Figure 2D). In fact hairpin 2 appeared to stimulate ORF37
expression in one experiment leading to the large error bar.
However, this experiment shows that inhibition of reactivation
cannot account for the loss of KSHV in the supernatant. To
further rule out an effect of hairpin expression on genomic
replication we also measured intracellular KSHV episomes by
DNA Q-PCR for ORF37 (Figure 2E) This control confirmed that
the number of KSHV episomes in the cells did not account for the
K5 hairpin induced defect in KSHV release and supports the
notion that K5 antagonizes tetherin.
These results suggest that K5 is required for efficient KSHV
particle release in a cell line that constitutively expresses tetherin
and that expressing increasing amounts of exogenous tetherin
further inhibits KSHV release. Together our data suggest that
tetherin has antiviral activity against KSHV and that K5 has an
important role in overcoming tetherin-mediated restriction.
K5 can substitute for Vpu in rescuing HIV-1 particle
release from tetherin-mediated restriction
Having established a role for K5 in counteracting tetherin
during KSHV release we then tested whether K5 expression could
functionally substitute for the HIV-1 encoded tetherin antagonist
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Figure 2. RNAi-depletion of K5 during lytic replication suppresses KSHV particle release. (A) Three shRNA hairpins were designed to
target K5 and co-expressed with K5-HA in 293T cells. The efficiency of reduction of K5 expression was assessed 48 hours later by western blot of total
cell lysates detecting the HA tag. Stripped blots were re-probed for alpha tubulin to demonstrate equal loading. (B & C) r219-HeLa cells were
transduced by lentiviral vectors encoding K5 shRNAs at an MOI of 5, reseeded 72 hours later and transfected with RTA expression plasmid the
following day. Supernatants were harvested 48 hours post-RTA transfection and KSHV titer expressed as infectious unit/ml (B) and DNase-I resistant
genome copies/ml (C) were determined as in Figure 1. At the time of harvest (48 hours post RTA transfection), ORF37 and GAPDH mRNA were
measured in the cell lysates by Taqman Q-RT-PCR to assess effect of the hairpins on KSHV reactivation and ORF37 expression (D). At the time of
harvest, cells were also kept to assess the effect of the hairpins on genome replication. Cellular DNA was extracted and KSHV episomes measured by
QPCR for ORF37 (E). Results are expressed as KSHV genomes per nanogram of total cellular DNA. Results are the mean of 2 independent experiments
and errors are standard error of the mean.
doi:10.1371/journal.ppat.1000843.g002
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Vpu and rescue the release of tetherin restricted HIV-1(delVpu)
particles [5]. We transfected HeLa cells with the HIV-1 molecular
clone NL4.3, or a Vpu-defective counterpart, together with
expression vectors for HA-tagged K5 or Vpu. As predicted, K5
expression potently rescued HIV-1(delVpu) release to levels
achieved by Vpu expression (Figure 3A). This was evidenced
both by measurement of HIV-1 p24 capsid protein released into
the supernatant by western blots as well as by titration of infectious
HIV-1 virus released into the supernatant on sensitive indicator
cells (Figure 3A, B and C). Importantly K5 expression had no
effect on wild-type HIV-1 particle release or on HIV-1 structural
protein expression. These data demonstrate that K5 is a functional
homolog of HIV-1 Vpu and that KSHV encodes a tetherin
countermeasure.
The fact that K5 has been demonstrated to be a RING
dependent E3 ligase for ubiquitin [20] suggested that the RING-
CH domain is important for its function. We therefore made a
RING deletion mutant of K5 (K5delRING) and tested its ability to
counteract tetherin restriction in an HIV-1 release assay as above.
Despite similar expression levels of the mutant and wild type K5
proteins (Figure 3B), the RING-defective K5 was unable to rescue
HIV-1(del Vpu) release from HeLa cells (Figure 3A and C). To
confirm that K5 can antagonize tetherin function we repeated the
experiment but in a tetherin-deficient cell line (HT1080) [5] stably
expressing a tetherin protein in which an HA-tag had been
inserted into the ectodomain at amino acid position 154 [9]. HT/
THN-HA cells were then transduced with retroviral vectors co-
expressing DsRed and Vpu, or K5 or K5delRING at doses
sufficient to give .90% DsRED-positive cells as demonstrated by
flow cytometry 48 hours later. The cells were then re-seeded and
infected with VSV-G pseudotyped HIV-1(wt) or HIV-1(del Vpu)
at a multiplicity of infection of 0.2. Since HT1080 cells are devoid
of CD4, VSV-G pseudotyping allows the measurement of a single
round of viral replication. Similar to the experiment in HeLa cells,
HT/THN-HA released HIV-1(del Vpu) particles approximately
20 fold less efficiently than they released wild type virus.
Furthermore, expression of either K5 or Vpu, but not K5delR-
ING, could rescue the tetherin mediated defect in virus release
(Figure 3D and E). Measurement of gag levels in supernatants and
extracts of infected cells by western blot indicated that the effects of
Figure 3. K5 rescues Vpu-defective HIV-1 particle release from tetherin mediated restriction. (A, B and C) HeLa cells were co-transfected
with HIV-1wt or HIV-1(del Vpu) proviral plasmids in combination with empty vector, or expression vector encoding Vpu, HA-tagged K5 or K5 lacking
the N-terminal RING domain. 48h post-transfection cell lysates and pelleted supernatants were analysed for HIV-1 Gag proteins by western blot using
an anti-p24CA monoclonal antibody (A) or an anti-HA monoclonal (B). Viral supernatants were also used to infect HeLa-TZM indicator cells and
infectious viral release determined by relative beta-galactosidase activity 48h later (C). (D and E) HT1080 cells stably expressing human tetherin
(HT1080/THN-HA) were transduced with retroviral vectors encoding both dsRED and either Vpu, K5 or K5(del RING) at doses sufficient to give .90%
transduction as determined by flow cytometry. Cells were then infected with HIV-1wt or HIV-1(del Vpu) pseudotyped with VSV-G at an MOI of 0.2. Cell
lysates and supernatants were processed as in (A) 48h later.
doi:10.1371/journal.ppat.1000843.g003
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tetherin, Vpu and K5 were on HIV-1 release and not gag protein
expression. Intriguingly, K5 could not antagonize tetherin
function in transiently-transfected 293T cells, even when tetherin
expression was titrated to vary its expression level (Figure S1). We
propose that 293T cells lack a co-factor essential for K5’s
antagonism of tetherin, but not for Vpu function. Interestingly,
293T cells are also unable to support HIV-2 Env’s anti-tetherin
activity [32], suggesting that this particular cell line might be
poorly suited for characterization of some tetherin antagonists.
Species-specific down-regulation of cell surface tetherin
by K5
Vpu has been shown to remove tetherin from the cell surface after
transfection [6] and in HIV-1-infected cells [32]. We therefore
tested whether K5 expression had the same effect on surface
tetherin levels in HT/THN-HA cells by expressing K5 via retroviral
transduction. Both K5 (Figure 4A) and HIV-1 Vpu (Figure S2)
expression led to a marked reduction of tetherin from the cell
surface. Importantly, the K5delRING protein was inactive in this
assay as predicted by data in Figure 3. HIV-1 Vpu-mediated
tetherin antagonism displays distinct species specificity for primate
tetherin genes with non-human primate orthologues being largely
insensitive to HIV-1 Vpu [18,19,33]. Sensitivity to HIV-1 Vpu
maps to the tetherin transmembrane domain and mutation of the T
residue at position 45 to the I present in Rhesus macaques (T45I)
coupled with an in frame deletion of a GI pair at the N-terminus of
the human tetherin protein’s TM (delGI-T45I) results in a human
tetherin that is completely resistant to HIV-1 Vpu [18] (Figure S2).
We therefore examined whether K5 also displays similar species–
specific effects (Figure 4B). Unlike HIV-1 Vpu, K5 was able to
down-regulate the THN(delGI-T45I) mutant human tetherin.
However, K5 was unable to down-regulate the rhesus macaque
tetherin protein. Thus K5 also displays species-specificity in its
antagonism of primate tetherins but the determinants of this
specificity are distinct from those of HIV-1 Vpu.
We then examined whether K5 could also down regulate
human tetherin from the surface of a B cell line carrying KSHV
(Figures 4C and D). Body-cavity-based lymphoma (BCBL) 1 cells
were transduced with a lentiviral vector encoding K5 or with an
empty vector and surface tetherin expression assessed by flow
cytometry analysis, using a specific antibody against human
tetherin. K5 expression led to a reduction of cell surface tetherin as
compared to the levels on cells treated with the empty vector or
levels detected on un-transduced cells (Figure 4C). The mean of
mean fluorescence intensity (MFI) values for 3 representative
experiments are also shown (Figure 4D).
K5 induces ubiquitin-dependent endolysozomal
degradation of tetherin
We next examined the fate of tetherin in K5-expressing cells.
HT/THN-HA cells were transduced to stably express K5 or Vpu
and intracellular levels of tetherin were compared to levels in
unmanipulated cells. Tetherin appears in western blots as a
heterogeneous smear of glycosylated species that varies between
cell types [10,17]. After K5 and Vpu expression, tetherin levels in
the modified cell lysates were decreased (to 4% of wildtype in the
case of K5 and to 31% of wildtype for Vpu), suggesting that, like
Vpu, K5 induces tetherin degradation (Figure 5A). At present it is
unclear whether Vpu induces tetherin degradation via a proteaso-
mal-dependent [19,34,35] or lysozomal pathway [36,37]. This is
further complicated by the fact that endolysozomal degradative
pathways are often also dependent on ubiquitin, and thus
proteasomal inhibition can inhibit them through depletion of free
cytoplasmic ubiquitin levels. We addressed the K5 mechanism of
action by examining the role of lysozomal degradation using the
vacuolar ATPase inhibitor bafilomycin A1 or by inhibiting
proteasomal degradation using MG132. We then measured steady
state levels of tetherin in K5 or Vpu expressing cells. A 16h
treatment with BafA1 or MG132 substantially rescued tetherin
levels from both Vpu and K5 expression. BafA1 treatment rescued
not only mature tetherin species, but also lower molecular weight
fragments that are likely to be partially degraded tetherin molecules.
This suggested that K5 degrades tetherin via an endolysozomal
process, similar to that by which it degrades Class I MHC [38]. The
rescue of tetherin degradation products in HT/THN-HA cells that
do not express HIV-1 Vpu or K5 suggested that endosomal
processing of tetherin contributes to its natural turnover. In contrast,
whilst MG132 treatment also rescued partially tetherin levels in
HT/THN-HA-K5 cells, mature species were predominant. In
Vpu-expressing cells MG132 appeared more potent for tetherin
rescue than BafA1, and again differential tetherin species were
rescued by each inhibitor. Together, these data suggest that while
tetherin degradation by K5 and Vpu are sensitive to both classes of
inhibitor, the stages of degradation that are affected are different.
Next we determined whether we could observe differences in
the cellular localization of tetherin induced by K5 or Vpu. In HT/
THN-HA cells, tetherin localized predominantly to the plasma
membrane with a small amount of the intracellular localizations
coincident with the late endosomal marker CD63 (Figure 5B) This
is consistent with the notion of natural tetherin turnover in
endolysozomal compartments. In K5 expressing cells, while
tetherin levels are markedly reduced, remaining tetherin was
much more often found associated with CD63+ late endosomes
than in controls (Figure 5B), implicating K5-induced endosomal
degradation. In contrast, in Vpu-expressing cells, tetherin was
never observed in CD63+ endosomes, but instead localized
predominantly to compartments that stain positive for the
Trans-Golgi marker TGN46 (Figure 5B and C). This localization
is similar to that observed after expression of the HIV-2 and
SIVtan envelope glycoproteins [32,39]. Thus, the subcellular
localization of tetherin after K5 expression suggests that K5 causes
it to be delivered to late endosomes for degradation. Importantly,
this distinguishes K5 and Vpu-induced tetherin antagonism and
implies distinct mechanisms.
Since the RING domain of K5 is required for tetherin down-
regulation from the cell surface, and degradation is sensitive to the
drug MG132, which also causes ubiquitin depletion, we
hypothesized that K5 mediated ubiquitination might drive
tetherin delivery to late endosomes. We therefore examined
whether proteasomal or lysozomal inhibition could rescue cell-
surface tetherin levels (Figure 5D). We found that whilst
endosomal inhibition with BafA1 treatment rescued tetherin
protein in the cell extracts of K5 expressing cells (Figure 5A)
neither BafA1 or concanamycin A could rescue tetherin levels at
the cell surface (Figure 5D). However, consistent with a role for
ubiquitination in the delivery of tetherin for endosomal degrada-
tion, MG132 treatment of tetherin-expressing cells did substan-
tially rescue tetherin levels at the surface of K5-expressing cells
(Figure 5D and E). In contrast, none of the inhibitors significantly
rescued tetherin surface expression in Vpu-expressing cells. These
observations demonstrate that K5-induces an endosomal degra-
dation of tetherin and suggest that an ubiquitin dependent process
is required for its delivery into this pathway. Conversely, HIV-1
Vpu causes tetherin degradation by a distinct mechanism that is
associated with its localization to the TGN (Figure 5B–C).
Next we asked whether the double-tyrosine based endocytic
motif in the tetherin cytoplasmic tail was required for K5-
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Figure 4. K5 mediates cell-surface down-regulation tetherin. (A) HT1080/THN-HA cells were transduced with retroviral vectors encoding
dsRED and either K5 or K5(del RING). 48h post-transduction the cells were immunostained for surface tetherin using an anti-HA monoclonal antibody
and an Alexa-488-conjugated goat-anti-mouse secondary antibody. Surface expression of tetherin was then analyzed in the dsRED positive
population by flow cytometry. Parental HT1080 cells were used as a control for background antibody binding and are represented by the red line.
Tetherin levels in HT1080 cells expressing tetherin alone are indicated by the purple line and levels of tetherin after K5 expression is represented by
the green line. (B) The same analyses were performed on HT1080 cells expressing the HA-tagged Vpu-resistant human tetherin (delGI,T45I) and
rhesus tetherin. Labeling is similar to panel A. (C) BCBL1 were transduced with a lentiviral vector expressing K5 (red line), an empty vector (black line),
or left untreated (grey peak), and cell surface expression of tetherin detected by flow cytometry 48 hours later as described above. (D) Mean
fluorescence intensity (MFI) values from (C) are also shown.
doi:10.1371/journal.ppat.1000843.g004
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Figure 5. Effects of proteasomal and endosomal inhibitors on tetherin levels and localization in cells expressing K5 and Vpu. (A)
Western blots of cell lysates from HT/THN-HA cells and isogenic pools stably expressing K5 or Vpu from retroviral vectors. Cells were treated for 16h
with BafA1 (100nM), MG132 (1mg/ml) or DMSO as a control, lysed and separated by SDS-PAGE. THN-HA was detected by anti-HA polyclonal antibody,
with Hsp90 serving as a loading control and visualized using Licor fluorescently coupled 650 and 800 nm secondary antibodies. Percent mature
tetherin levels, normalized to Hsp90 loading are displayed below each lane. (B) Representative examples of HT/THN, HT/THN-HA K5 and HT/THN-HA
Vpu cells immunostained for tetherin with a rabbit anti-HA antibody (red) and an antibody for the late endosomal marker CD63 (green). Nuclei were
counterstained with DAPI (blue) and cells examined by confocal microscopy. (C) HT/THN-HA Vpu cells stained for THN-HA (green) and the trans-Golgi
marker TGN46 (red) were processed as above. (D) Cells from A were surface stained for tetherin levels and analyzed by flow cytometry. Purple
histograms represent tetherin levels on DMSO treated cells. Green overlays indicate tetherin levels after treatment with the indicated drug. The pink
histogram overlays show the levels of tetherin on untreated HT/THN-HA from the upper row for comparison. (E) Confocal image of a representative
HT/THN-HA K5 cell treated with MG132 and stained for THN-Ha (red) and CD63 (green). (F) HT/THN-HA Y6,8A were imaged by confocal microscopy
for tetherin (red). The cells were then manipulated to express K5 and analyzed by flow cytometry for surface tetherin and by western blot for total
cellular tetherin levels.
doi:10.1371/journal.ppat.1000843.g005
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mediated degradation. This motif binds the clathrin adaptors AP1
and AP2 and has been reported to be important for tetherin
endocytosis and recycling [40]. HT1080 cells expressing THN-HA
Y6,8A were generated and tetherin localization determined by
immunofluorescence microscopy. As expected this mutant tetherin
was found almost exclusively at the plasma membrane (Figure 5F).
Interestingly, expression of K5 in these cells still led to significant
tetherin down-regulation and degradation (Figure 5F) as demon-
strated by flow cytometry and western blot. Thus tetherin
trafficking to late endosomes induced by K5 is independent of
its endocytic motif, suggesting that K5 targets tetherin for
degradation via a pathway that is independent from its normal
subcellular trafficking.
Delivery to late endosomes and antagonism of antiviral
activity by K5 is dependent on a single lysine residue in
the tetherin cytoplasmic tail
K5 targeting of class I MHC molecules depends on membrane
proximal lysine residues in their cytoplasmic tails [20]. Tetherin
also has two membrane proximal lysines, K18 and K21. To seek a
role for these residues we mutated them to arginine, singly or in
combination, in THN/HA and stably expressed these mutant
tetherins in HT1080 cells. We then stained the cell surface tetherin
via the HA tag and measured cell surface tetherin levels by flow
cytometry (Figure 6A). All tetherins were expressed at the cell
surface, but the lysine mutants were expressed at enhanced levels
as compared to the wild-type protein. This suggested that these
two lysines might be involved in natural tetherin turnover. When
K5 was expressed in the mutant tetherin cell lines, tetherin down-
regulation was almost completely prevented for proteins bearing a
K18R substitution. In contrast, K21R mutation had no effect on
K5-induced cell surface down-regulation. Furthermore, K21R but
not K18R or K18,21R mutants were consistently redistributed to
CD63+ compartments upon K5 expression (Figure 6B). We then
further examined whether K5 retained the ability to disrupt
tetherin function in the absence of cell-surface tetherin down-
regulation, as has been suggested for Vpu [17]. HT/THN-HA
and HT/THN-HA K18R cells expressing either K5 or Vpu were
infected with HIV-1wt and HIV-1(delVpu) VSV-G pseudotyped
Figure 6. K18 in the tetherin cytoplasmic tail is required for K5-mediated cell surface down-regulation and delivery to endosomes. (A)
Flow cytometry analyses of HT1080 cells expressing wild type tetherin or the indicated mutant. Purple histograms represent THN-HA levels on
unmanipulated cells, with the green overlay showing tetherin levels in the equivalent cells stably expressing K5. Red histograms represent the antibody
isotype control. (B) Representative examples the cells from (A) were stained for THN-HA (red) and CD63 (green) and examined by confocal microscopy.
doi:10.1371/journal.ppat.1000843.g006
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viruses at an MOI of 0.2. Supernatants were collected 48h later
and infectious virus output was measured on HeLa-TZM cells.
THN-HA K18R expressing cells restricted Vpu-defective HIV-1
release similarly to the wild type protein, however expression of
K5 failed to rescue the release of HIV-1(delVpu) from HT/THN-
HA-K18R cells (Figure 7A). By contrast Vpu-mediated antago-
nism of tetherin was unaffected by mutation of K18 in HT1080
cells (Figure 7A) or indeed either of the lysine residues in 293T
cells (Figure 7B). Thus, removal of tetherin from the cell surface
and delivery to late endosomes is required for K5-mediated
antagonism of its antiviral action and this is dependent on the
lysine at position 18. Measurement of gag levels in cell extracts and
supernatants by western blot demonstrated that tetherin expres-
sion did not impact on gag expression (Figure 7C). Measurement
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of tetherin levels ensured that tetherin was expressed as expected
(Figure 7C).
Since lysine residues serve as targets for ubiquitination we
next sought evidence for tetherin ubiquitination in the presence
of K5. HeLa cells were transfected with THN-HA or THN-HA
K18, 21R in the presence of an ubiquitin bearing a 6-histidine
tag. The cells were treated for 8h with BafA1 to block tetherin
degradation and ubiquitinated proteins were isolated by
incubating whole cell lysates with nickel-agarose beads. In the
presence of either co-transfected K5 or Vpu, THN-HA
molecules could be isolated from the transfected cells
(Figure 8). The tetherin predominantly formed a single species
at a size suggestive of mono-ubiquitination. Interestingly, we
failed to pull down ubiquitinated tetherin molecules when their
cytoplasmic lysine residues had been mutated, after either K5 or
Vpu transfection. This implies that the action of both K5 and
Vpu leads to ubiquitination of the tetherin cytoplasmic tail. In
the case of K5, this suggests that ubiquitination of K18
antagonizes tetherin-mediated restriction and directs it to
endosomal compartments for degradation. Intriguingly, mutat-
ing the lysine residues does not make tetherin insensitive to Vpu
suggesting that tetherin becomes ubiquitinated as a consequence
of tetherin antagonism by HIV-1 Vpu but that this ubiquitina-
tion is not required for the antagonistic process.
K5-mediated down-regulation of tetherin is sensitive to
inhibition of the ESCRT pathway
There are several ubiquitin-dependent mechanisms by which
K5 might achieve tetherin degradation. For example, ubiquitina-
tion of tetherin’s cytoplasmic tail could stimulate its internalization
and mediate classical recruitment of the ESCRT pathway through
engagement of TSG101, as has been shown for K3 targeting of
MHC I [41]. This would lead to the budding of tetherin
containing vesicles into the lumen of multivesicular bodies for
degradation in lysozomes [42]. To examine the role of the ESCRT
pathway in K5-mediated tetherin degradation, we tested whether
K5-mediated loss of tetherin from the cell surface was sensitive to
expression of a dominant negative form of VPS4. VPS4 is the
essential AAA-ATPase that provides the energy for ESCRT
disassembly and recycling during the final membrane scission
event in the sorting of cell surface receptors for endosomal
degradation [43]. Co-transfection of HeLa cells with GFP-
dnVPS4(E228Q) [44] substantially rescued cell surface tetherin
levels from K5 as assessed by flow-cytometry (Figure 9A and B).
Expression of K5delRING has no effect on THN cell surface
expression, concordant with Figure 4, and neither does the
dominant negative VPS4 protein when expressed with the tetherin
RING mutant. Together with the demonstration that K5 leads to
tetherin ubiquitination and degradation, these observations
strongly suggest that K5 induces a VPS4 and ubiquitination-
dependent trafficking of tetherin from the cell surface to late
endosomes for destruction. Importantly, this mechanism is similar
to that used by K3 to down-regulate Class I MHC molecules
[38,41].
Discussion
Tetherin has emerged as a potent inhibitor of enveloped virus
release [5,6,9,12,13]. Recent evidence has demonstrated that
tetherin dimers act as a physical linkage between the membranes
of the infected cell and nascent virions [10]. This mechanism lends
itself well to a general non-specific antiviral inhibition that restricts
virus release and thereby interferes with viral spread to new target
cells. It also suggests that mammalian viruses may not be able to
easily mutate to avoid tetherin because tetherin does not directly
interact with any viral structural proteins. Sensitive viruses must
therefore evolve specific ways of counteracting it. In the case of
primate lentiviruses, several tetherin antagonists have now been
identified. The Vpu accessory protein antagonizes tetherin in
HIV-1 infected cells [5,6], whereas in a variety of SIVs that do not
encode a Vpu gene, the Nef protein can overcome the tetherin
orthologues from their host species [33,45]. Interestingly, HIV-2
[32] and at least one strain of SIV [39] have acquired the ability to
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Figure 8. Tetherin cytoplasmic tail lysine residues are ubiquitinated in the presence of K5 and Vpu. HeLa cells were transiently
transfected with the indicated THN-HA expression vector in combination with K5, Vpu or GFP and in the presence or absence of 6His-tagged
ubiquitin. 48h after transfection, cells were treated for 8 hours with BafA1 (100nM) to prevent tetherin degradation. Cell lysates were then harvested
and ubiquitinated proteins were isolated by binding to Ni-Nti-agarose. Cell lysates and pull-downs were analyzed by western blot for THN-HA
detecting the HA tag.
doi:10.1371/journal.ppat.1000843.g008
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antagonize tetherin with their envelope glycoproteins. Outside the
Retroviridae, the ebolavirus glycoprotein has anti-tetherin activity
[13] and here we propose that human herpesvirus KSHV
antagonizes tetherin with K5.
While this study was in revision, a study from Mansouri and
colleagues showed that tetherin could be degraded by K5 in an
ubiquitin-dependent manner [46]. Our data demonstrate that K5
can fully substitute for Vpu in mediating the efficient release of
HIV-1 particles from tetherin-expressing cells. This requires the
K5 RING domain and leads to a cell-surface down-regulation of
tetherin followed by its degradation in endosomal compartments.
Down-regulation of tetherin by K5 and its targeting to
endosomes requires the membrane proximal lysine residue K18
in the cytoplasmic tail, and this process is sensitive to inhibition of
the proteasome with MG132. Since K5-induced ubiquitination of
tetherin is dependent on its cytoplasmic tail lysines, the effects of
proteasomal inhibition are likely to be due to depletion of
cytoplasmic ubiquitin levels, rather than blocking proteasomal
degradation of tetherin. Furthermore, K5-mediated tetherin
degradation requires a functional ESCRT pathway as shown
by the rescue of surface tetherin levels after expression of a
dominant negative VPS4 protein. These observations suggest that
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Figure 9. Cell-surface down-regulation of tetherin by K5 is inhibited by dominant-negative VPS4. (A) HeLa cells were transfected with
wild type K5 or K5(del RING) expression vectors in combination with either GFP or a dominant negative mutant of VPS4 fused to GFP (VPS4 E228Q).
24h later cells were stained for cell surface tetherin using anti-BST2 monoclonal antibody and a goat-anti-mouse Alexa633 secondary antibody. Flow
cytometry dot plots are shown. (B) The mean florescent intensities (MFI) of surface tetherin expression in GFP positive and GFP negative populations
from the samples in panel A are plotted.
doi:10.1371/journal.ppat.1000843.g009
Antagonism of Tetherin by KSHV K5
PLoS Pathogens | www.plospathogens.org 12 April 2010 | Volume 6 | Issue 4 | e1000843
K5 targets tetherin by inducing an ubiquitin-dependent sorting of
tetherin to multivesicular bodies where it is destroyed in a
lysozomal compartment, a similar mechanism to that of K3-
mediated degradation of Class I MHC molecules [41]. K3 targets
MHCI for ESCRT-dependent sorting and destruction via
addition of a single ubiquitin moiety to the molecule’s
cytoplasmic tail through recruitment of the E2 enzymes UbcH5B
and/or C [38]. Lysine-63 poly-ubiquitination is then induced
through the subsequent recruitment of Ubc13 [38]. While we
cannot rule out that K5 induces poly-ubiquitination of tetherin,
we were only able to observe species consistent with mono-
ubiquitination. Thus, while K5 induces ESCRT-dependent
tetherin degradation, the precise molecular details of the
endosomal targeting may differ between K3 and K5 targets.
Whether endocytosis of tetherin is stimulated by K5, or whether
it is routed to endosomes from the Golgi, bypassing the cell
surface remains an interesting question. Our observation that
surface down-regulation of tetherin is independent of its tyrosine-
based endocytic-sorting signal [40] suggests the latter. Since K5
localizes mainly to the ER [47], tetherin ubiquitination could
happen very early after synthesis leading to endosomal routing
independently of the cell surface. Similarly, Mansouri and
colleagues suggested that in K5-expressing cells, little tetherin
reaches the PM, based on surface biotinylation experiments [46].
However, neither of these results is unambiguous, especially if cell
surface turnover is fast. Further studies of the molecular details of
K5 mechanism are required to fully dissect its effects on tetherin
trafficking.
An important aspect of our study is the comparative analysis of
the mechanisms by which Vpu and K5 achieve tetherin
antagonism. Both proteins lead to cell surface down-regulation
and degradation of tetherin but the mechanism of Vpu remains
unclear. Several studies have shown that tetherin degradation is
blocked by proteasomal inhibition [19,34,35], whereas others
suggest endosomal degradation [36,37]. It is clear that whilst Vpu-
mutants that cannot interact with bTRCP2 cannot mediate
tetherin degradation [36,37], they can nonetheless antagonize
tetherin and rescue viral release [17]. Thus, the SCF-Skp1-cullin 1
ubiquitin ligase complex and perhaps an ER-associated degrada-
tive pathway are implicated in tetherin degradation and this
process presumably follows tetherin antagonism at the cell surface
[35,36]. Tetherin down-regulation and degradation might there-
fore not be as strictly linked during Vpu-mediated antagonism as it
is during K5 mediated antagonism of tetherin. Furthermore,
proteasomal inhibition appeared to be more potent than
endosomal inhibition in rescuing cellular levels of tetherin in
Vpu-expressing cells. Unlike K5, we saw no evidence of tetherin
redistribution to endosomes in response to Vpu. Rather, residual
tetherin can be seen in the TGN, consistent with a recent study
suggesting that Vpu localization to the TGN is important for
tetherin antagonism [48]. Similarly, proteasomal inhibition does
not restore tetherin to the surface of Vpu-expressing cells, and
neither does dominant negative VPS4 (not shown). Also consistent
with these observations, is our observation that Vpu can induce
ubiquitination of tetherin cytoplasmic tail lysine residues, but these
are dispensable for Vpu sensitivity. Thus their ubiquitination
appears to be a consequence of tetherin antagonism rather than
the absolute requirement for K18 demonstrated for K5 sensitivity.
In this respect, we suggest tetherin antagonism by Vpu precedes,
and may not be dependent on, degradation, but rather results in
the sequestration of tetherin away from budding virions,
preventing incorporation. Thus there are more parallels with the
mechanism by which HIV-2 and SIVtan envelopes antagonize
tetherin through sequestration in TGN-associated compartments
[32,39]. K5’s apparent inability to antagonize tetherin in 293T
cells, cells that support Vpu’s antagonism of tetherin, suggests that
Vpu and K5 may require different cellular cofactors. Clearly,
further comparative mechanistic studies will allow us to dissect the
differences and similarities in the mode of action of these two very
different proteins.
We, and others [46], have also shown that productive KSHV
release is restricted by tetherin expression and knockdown of K5
expression imparted a block to virus release. Furthermore,
tetherin expression is reduced on B cells after K5 expression.
Importantly, this indicates that herpesvirus particle assembly is
sensitive to the antiviral effects of tetherin. The mechanism of
herpesvirus assembly and envelopment is complex and contro-
versial, most studies have focused on herpes simplex virus type 1
(HSV-1). Immature HSV-1 capsids may bud through nuclear
membrane, re-entering the cytoplasm, and then bud again into
secretory vesicles [29] via an ESCRT dependent process [49].
Our data suggest that in the case of KSHV, at least one budding
stage is through a membrane accessible to tetherin. Tetherin is
highly expressed in terminally differentiated B cells and plasma
cells, important cellular targets for KSHV [50]. B cell to plasma
cell differentiation activates KSHV lytic replication through the
activation of XBP-1 and the unfolded protein response [51].
Therefore the virus undergoes productive replication in cells
that express high levels of tetherin. This cellular tropism may
have provided the selective pressure for K5 evolution to target
tetherin. K5 has the ability to modulate the expression of a
variety of cell surface molecules involved in immuno-recognition
(MHC and NK receptors) and cell adhesion, suggesting
targeting of tetherin is part of a wider immuno-evasion strategy
by KSHV [52]. Is tetherin antagonism found in other
mammalian herpesviruses? B cell expression of tetherin would
certainly suggest that this might be the case for Epstein Barr
Virus (EBV). Removal of MHC and related molecules is
certainly a common feature of several human herpesvirus
immune evasion strategies [52,53,54], and it is likely that if
other herpesviruses are sensitive to tetherin-mediated restric-
tion, proteins with analogous function to K5 might also target
tetherin. MARCH ligase homologues are also found in a variety
of poxviruses [20], which also have highly complex envelopment
strategies [55].
Aside from the cytoplasmic tail lysine residue K18, we do not
yet fully understand the determinants of sensitivity for tetherin’s
antagonism by K5. Data presented herein show that while K5,
like Vpu [18,19], cannot target tetherin from Rhesus macaques,
the TM domain positions that determine the difference in Vpu-
sensitivity do not confer resistance to K5. Tetherin has been
under high levels of positive selection during mammalian
evolution, particularly in the cytoplasmic tail and TM domain,
areas of the protein likely to be topologically accessible to viral
antagonists [18,19]. Several residues in the TM domain are
responsible for the species-specific activity of Vpu. However,
positive selection in other parts of tetherin may be due to selective
pressure exerted by distinct viral countermeasures. We speculate
that some mammalian herpesviruses, which show strong co-
evolution with their hosts, may have contributed to this
evolutionary pressure. Tetherin may therefore represent an
extremely interesting case study in the evolution of an antiviral
gene under regular assault by unrelated viral pathogens, as has
been suggested for PKR [56].
In conclusion, here we have demonstrated that tetherin is
capable of restricting a human herpesvirus and show that in the
case of KSHV, the virus has co-opted an immuno-modulatory
ubiquitin ligase to target this antiviral effector.
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Materials and Methods
Plasmids, cells and antibodies
All adherent cells were maintained in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% fetal calf serum
and antibiotics. BCBL-1 cells were maintained in Roswell Park
Memorial Institute (RPMI) medium supplemented with 10% FCS
and antibiotics. HeLa, 293T and HT1080 cells were obtained
from the ATCC. The HIV-1 indicator cell line, HeLa-TZM, that
expresses HIV-1 receptors and an integrated HIV-1-LTR
controlling expression of a beta-galactosidase reporter gene were
kindly provided by John Kappes and Xiaoyun Wu via the NIH
AIDS reagents program. HT1080/THN-HA is a clonal cell line
expressing human tetherin with an internal HA tag inserted at
nucleotide position 463 [18] expressed from an integrated MLV
proviral vector, pLHCX (Clontech). Mutants of tetherin were
constructed by standard methods and expressed from pCR3.1 and
pLHCX. Vpu, K5 and a K5 mutant lacking amino acids 1–62
encompassing the RING domain (K5delRING) were amplified by
PCR and inserted into pCR3.1 with C-terminal HA and mCherry
fusion tags and the retroviral vectors pCxCR, which also encodes
dsRED express as a marker gene, and pCMS28, a pMigR1
derivative encoding puromycin under control of an Internal
Ribosome Entry Site (IRES). The molecular clones of HIV-1
NL4.3 and the Vpu-defective counterpart have been described
previously [7]. Anti-HA monoclonal antibody HA1.11 was
obtained from Covance, rabbit anti-HA polyclonal was obtained
from Rockland and anti-BST2 monoclonal antibody was obtained
from Abnova. Secondary Alexa Fluor 488, 594 and 633 antibodies
for flow cytometry and microscopy were obtained from Molecular
Probes. For quantitative western blotting, Licor 680 and 800nm
secondary abs were used and blots scanned using a Licor scanner.
Production of KSHV
HeLa cells infected with KSHV were made by infecting HeLa
with rKSHV.219 a recombinant KSHV virus encoding RFP, GFP
and puromycin resistance, a gift from Jeff Vieira [30]. Cells were
selected and kept under puromycin selection. To induce
rKSHV.219 into the lytic cycle, r219-Hela cells were seeded at
3.105 cells/well onto 6-well plates and transfected with 1.5 mg of
an expression factor for RTA (pCMV-RTA) (a gift from Adrian
Whitehouse) using Fugene-6. RFP expression was visible a day
after transfection. The transfection mix was removed and replaced
with 2 ml of fresh medium. Virus was recovered another 24 hours
later, i.e. 48 hours after transfection, and filtered through 0.45 mM
device (Millipore) to remove any cellular debris. Infectious virus
was measured by titration of supernatants onto 293T cells and
total virus by QPCR on DNAse-I resistant genomes. To assay for
KSHV release in the presence of tetherin, r219-Hela cells were
transfected with pCMV-RTA and increasing doses of tetherin
expression vector pCR3.1-THN [5]. Plasmid dose was kept
constant using empty vector (pCDNA3.1). To assay for KSHV
release under conditions where K5 expression is reduced, r219-
Hela cells were seeded at 105 cells per well in 6-well plates
24 hours prior to transduction with the lentiviral vectors encoding
the K5 specific hairpins, or the empty vector, at a multiplicity of
infection (MOI) of 5. 72 hours post-transduction, cells were
counted, re-seeded into 6-well plates and transfected with RTA
encoding plasmid as above.
Quantitation of KSHV infectious particles by titration
onto 293T
293T cells were seeded at 105 cells/well in 12-well plates
24 hours prior to titration. For each viral collection 250 ml (a sixth)
of the final volume of filtered virus was added to fresh medium to a
final volume of 1 ml and used to infect 293T cells. Titrations were
performed in duplicate using polybrene (4mg/ml). 12-well plates
were subjected to spinoculation at 500 g for 1 hour at RT before
being returned to the incubator. Cells were analyzed by flow
cytometry 48 hours post-inoculation.
Quantitation of KSHV genomes by Taqman PCR against
KSHV early gene ORF37
KSHV genomes were quantified by extracting total DNA
(QIAamp, QIAGEN) from DNAse-I treated supernatant (70
units/ml for 2 hours, RQ1 Promega, UK) with 40mg of salmon
sperm DNA as a carrier (Sigma, Poole UK). 5mg of purified DNA
was subjected to quantitative Taqman PCR for KSHV early gene
ORF37 as described [57]. Absolute copy number was determined
with reference to a standard curve derived by QPCR against serial
dilutions of an ORF37 amplicon encoding plasmid, a gift from
David Bibby and Duncan Clark, as described [58].
Quantification of mRNA levels for the late gene ORF37 in
r219-HeLa cell lysates by Q-RT-PCR
Total mRNA was extracted from r219-HeLa cells after virus
collection, 48 hours post-RTA transfection (RNeasy, QIAGEN).
cDNA syntheses were performed on 4 ml of the RNA (SuperScript
II Reverse Transcriptase, Invitrogen) according to manufacturer’s
instructions. cDNAs were treated with 2 units of RNAse H
(Invitrogen) for 20 minutes at 37uC before being used in taqman Q-
PCR reactions for ORF37 and GAPDH. GAPDH primers were
GAPDH forward primer, 59-GGCTGAGAACGGGAAGCTT-39;
GAPDH reverse primer, 59-AGGGATCTCGCTCCTGGAA-39;
GAPDH probe, 59-FAM-TCATCAATGGAAATCCCATCACC-
A-TAMRA-39. Absolute copy number was determined with
reference to a standard curve derived by QPCR against serial
dilutions of a GAPDH amplicon encoding plasmid. QPCR for
ORF37 was performed as described above.
Quantification of the number of episomes per nanogram
of total DNA in r219-HeLa cells
Cellular DNA was extracted from r219-HeLa cells after virus
collection, 48 hours post-RTA transfection (QIAamp, QIAGEN)
and QPCR for ORF37 performed, as described above, on cellular
associated episomes. Copy numbers were normalized to quantities
of DNA used for each reaction.
Production of retroviral vectors and infectious HIV-1
(VSV-G pseudotypes)
Semi-confluent 293T cells on 6-well dishes were transfected
with 1mg of vector plasmid, 1mg of pMLVgag-pol or p8.91
(HIV-1 gag-pol, tat and rev expression vector) and 0.2mg
pCMV-VSVG. For full length replication competent HIV-1
(VSV-G) pseudotypes, 293T cells were transfected with 2mg of
pNL4.3 or pNL4.3(del Vpu) and 0.2mg of VSV-G. This leads
to production of replication competent HIV-1 that has both
VSV-G and HIV-1 gp160 envelope proteins on its surface.
Virus and vector stocks were harvested 48h post-transfection.
Those encoding florescent markers were titrated on HT1080
cells and analyzed by flow cytometry; lentiviral vectors
encoding shRNA hairpins were titered by Q-PCR on 293T
cells with primers specific for the HIV-1 LTR; and the
endpoint titer of full length HIV-1 pseudotypes was deter-
mined on HeLa-TZM cells by staining infected foci with X-Gal
48h post-infection.
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HIV-1 release assays
Subconfluent HeLa cells were transfected with 500ng of HIV-1
proviral plasmid and 100ng of pCR3.1-Vpu or pCR3.1-K5-HA/
K5delRING-HA using lipofectamine 2000 (Invitrogen). Viral
supernatants and cell lysates were harvested 48h later. Superna-
tant virions were filtered and pelleted at 30000g through 20%
sucrose/PBS cushion for 90 minutes. Lysates and virions were
then separated by SDS-PAGE and HIV-1 Gag proteins detected
using an anti-p24 monoclonal antibody CA183 (provided by B
Chesboro through the NIH AIDS Reagents repository). In
parallel, harvested supernatants were titered onto HeLa-TZM
indicator cells and 48 hours later beta-gal activity was determined
in cell lysates using a Tropix Beta-galactosidase activity kit
(Molecular Probes). For assays involving stable HT1080/THN-
HA cell lines, 105 cells were plated per well in a 12 well plate and
infected with 26104 infectious units (MOI 0.2) of HIV-1 (VSV-G)
or HIV-1(del Vpu)(VSV-G) viral stocks. 48h later cell lysates and
viral supernatants were treated as above.
Flow cytometry and confocal microscopy
Cell surface staining for tetherin and THN-HA was performed
using the appropriate antibodies by standard methods and
analyzed on a FACS-Calibur (Becton-Dickinson). Cells for
microscopy were grown on glass coverslips and transfected or
treated with BafA1 (100nM), concanamycin A (100nM) or MG132
(1mg/ml) (Sigma, UK) for 10h. The cells were then fixed in 4%
paraformaldehyde, permeabilized with 0.1% Triton-6100 and
stained with the required primary and secondary antibody. Cells
were then examined using a Zeiss confocal microscope.
Tetherin ubiquitination assay
HeLa cells seeded on 10cm plates were transiently transfected
with the indicated THN-HA expression vector (5ug) in combina-
tion with K5, Vpu or GFP (2mg) expression vectors and in the
presence or absence of a 6-His-tagged ubiquitin encoding plasmid
(2mg). 48h after transfection, cells were treated for 8h with BafA1
(Sigma) to prevent further tetherin degradation. Cells were lysed in
5M guanidinium hydrochloride, sonicated and ubiquitinated
proteins were isolated by binding to 50ml of Ni2+ Nti-agarose
(Invitrogen) for 3h at room temperature. The beads were eluted
with 100mM imidazole. Lysates and pull-downs were then
analyzed by western blot for THN-HA.
Supporting Information
Figure S1 K5 does not antagonize tetherin-mediated restriction
of HIV-1(del Vpu) in 293T cells. 293T cells were transfected with
wild type HIV-1 or HIV-1(del Vpu) proviral plasmids in
combination with either Vpu or K5 expression vectors and
increasing doses of pCR3.1 THN-HA. 48h later supernatant
infectivity was determined on HeLa-TZM cells and is shown
plotted against tetherin input.
Found at: doi:10.1371/journal.ppat.1000843.s001 (0.26 MB EPS)
Figure S2 Vpu mediates the surface down-regulation of THN-
HA but not THN-HA(delGI-T45I) or Rh-THN-HA in HT1080
cells. Surface expression levels of stably transduced HT1080 cells
expressing THN-HA, THN-HA(delGI-T45I) or Rh-THN-HA
and Vpu were measured by flow cytometry. The red line
represents staining in unmodified HT1080 cells, the purple
histogram represents tetherin expression levels in tetherin
expressing cells and the green line represents tetherin levels after
HIV-1 Vpu expression.
Found at: doi:10.1371/journal.ppat.1000843.s002 (0.29 MB EPS)
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